Changes in T-lymphocytes in lung cancer patients after hyperthermic intraperitoneal chemotherapy or radiotherapy

Genetics and Molecular Research

Volumn 15, Issue 2, 2016, Pages

  Yan, L ^a   Wu, M ^a   Ba, N ^a   Shi, G ^a   Wang, L ^a   Zhang, H ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

CD3+; CD4+; CD8+; Lung cancer; T lymphocytes

Indexed keywords

ADULT; ANTIBODY DETECTION; ARTICLE; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; T LYMPHOCYTE; THERMOTHERAPY; AGED; DRUG EFFECTS; IMMUNOLOGY; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; RADIATION RESPONSE; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERTHERMIA, INDUCED; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84975221210     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/gmr.15027865     Document Type: Article

References (22)

1. Azzoli CG, Baker S, Jr., Temin S, Pao W, et al.; American Society of Clinical Oncology (2009). American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27: 6251-6266. http://dx.doi.org/10.1200/JCO.2009.23.5622
2. Dushyanthen S, Savas P, Willard-Gallo K, Denkert C, et al. (2015). Tumour-infiltrating lymphocytes (TILs) in breast cancer: a predictive or a prognostic marker? Curr. Breast Cancer Rep. 7: 59-70. http://dx.doi.org/10.1007/s12609-014-0178-4
3. Grivennikov SI, Greten FR and Karin M (2010). Immunity, inflammation, and cancer. Cell 140: 883-899. http://dx.doi. org/10.1016/j.cell.2010.01.025
4. Homey B, Müller A and Zlotnik A (2002). Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2: 175-184. http://dx.doi.org/10.1038/nri748
5. Hyer JD and Silvestri G (2000). Diagnosis and staging of lung cancer. Clin. Chest Med. 21: 95-106, viii-ix. http://dx.doi. org/10.1016/S0272-5231(05)70010-1
6. Lissoni P, Brivio F, Fumagalli L, Messina G, et al. (2004). Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int. J. Biol. Markers 19: 135-140.
7. Liyanage UK, Moore TT, Joo HG, Tanaka Y, et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761. http://dx.doi.org/10.4049/jimmunol.169.5.2756
8. Mori M, Ohtani H, Naito Y, Sagawa M, et al. (2000). Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J. Exp. Med. 191: 113-118. http://dx.doi. org/10.1620/tjem.191.113
9. Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, et al. (2007). Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br. J. Cancer 97: 1135-1138. http://dx.doi. org/10.1038/sj.bjc.6604001
10. O'Rourke N and Edwards R (2000). Lung cancer treatment waiting times and tumour growth. Clin. Oncol. (R Coll Radiol) 12: 141-144. http://dx.doi.org/10.1053/clon.2000.9139
11. Paez JG, Jänne PA, Lee JC, Tracy S, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. http://dx.doi.org/10.1126/science.1099314
12. Pardoll DM (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252-264. http:// dx.doi.org/10.1038/nrc3239
13. Pasare C and Medzhitov R (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. http://dx.doi.org/10.1126/science.1078231
14. Phan GQ, Yang JC, Sherry RM, Hwu P, et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377. http://dx.doi.org/10.1073/pnas.1533209100
15. Rathore AS, Kumar S, Konwar R, Makker A, et al. (2014). CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J. Med. Res. 140: 361-369.
16. Rivera MP, Detterbeck F and Mehta AC; American College of Chest Physicians (2003). Diagnosis of lung cancer: the guidelines. Chest 123 (Suppl): 129S-136S. http://dx.doi.org/10.1378/chest.123.1_suppl.129S
17. Robinson LA, Ruckdeschel JC, Wagner H, Jr., Stevens CW, et al. (2007). Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 243S-265S.
18. Rosenberg SA, Yang JC and Restifo NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. http://dx.doi.org/10.1038/nm1100
19. Schaefer C, Kim GG, Albers A, Hoermann K, et al. (2005). Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92: 913-920. http://dx.doi.org/10.1038/ sj.bjc.6602407
20. Schoo WH and Coppes L (1976). Use of palatal mucosa and lyophilized dura mater to create attached gingiva. J. Clin. Periodontol. 3: 166-172. http://dx.doi.org/10.1111/j.1600-051X.1976.tb01864.x
21. Scott WJ, Howington J, Feigenberg S, Movsas B, et al. (2007). Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 234S-242S.
22. Yu DP, Han Y, Zhao QY and Liu ZD (2014). CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer. Asian Pac. J. Cancer Prev. 15: 2685-2688. http://dx.doi.org/10.7314/APJCP.2014.15.6.2685